Trials / Sponsors / AB2 Bio Ltd.
AB2 Bio Ltd.
Industry · 3 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Completed | Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension XIAP Deficiency, NLRC4-MAS | Phase 3 | 2018-01-24 |
| Completed | Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency NLRC4-MAS, XIAP Deficiency | Phase 3 | 2017-07-21 |
| Completed | Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease Still's Disease, Adult-Onset | Phase 2 | 2015-02-01 |